E-mail this
page to a friend!
Pfizer Takes Bextra Off Market at FDA Request
Agency orders new warning labels on Cox-2
and other NSAID medications
April 7, 2005 The Food and Drug
Administration today asked Pfizer to withdraw Bextra from
the market and announced new label warnings for the
non-steroidal anti-inflammatory class of drugs, including
COX-2 selective and prescription and non-prescription
(over-the-counter (OTC)) non-selective NSAID medications.
Read more...
FDA Urges Caution Using Cox-2 Inhibitors, Other
Anti-Inflammatory Drugs
New advisory issued as the increase investigation; advice for physicians
and patients issued
Dec. 23, 2004 - The Food and Drug Administration
today issued a Public Health Advisory summarizing the agency's
recent cautions and recommendations concerning the use of non-steroidal
anti-inflammatory drug products (NSAIDs), including those known as COX-2
selective agents. The public health advisory is an interim measure,
pending further review of data that continue to be collected.
More... 12/23/04
FDA
Delays Action on Celebrex, Waiting for More Info
Dec.
18, 2004 Late yesterday the Food and Drug Administration
issued a statement on the warning issued by Pfizer of possible
heart problems caused by their drug Celebrex, which is taken my
millions of senior citizens for pain relief, primarily that
caused by arthritis. The FDA says they are taking no regulatory
action now but will seek more information.
More... 12/18/04*
NIH Halts Use of COX-2 Inhibitor
in Large Cancer Prevention Trial
Dec.
18, 2004 -
The National Institutes of Health (NIH) announced
Friday that it has suspended the use of COX-2 inhibitor celecoxib
(Celebrex Pfizer, Inc.) for all participants in a large colorectal
cancer prevention clinical trial conducted by the National Cancer
Institute (NCI). More...
12/18/04*
Celebrex Caused Increase Heart Problem Risk:
Pfizer
Dec.
17, 2004 Celebrex has been found to cause increased risk of heart
problems, according to an announcement by Pfizer, maker of the
painkiller. Often used by senior citizens
with arthritis, Celebrex is in the same class as Vioxx, the drug
yanked off the market in September because of similar concerns.
More, including complete
company statement... 12/17/04*
Pfizer Claims Celebrex Safety in September:
Day Vioxx Recalled
Dec. 17, 2004 On September 30, the day Merck &
Co. announced the recall of its COX-2 drug, Vioxx, Pfizer issued a news
release expressing confidence that Celebrex did not cause heart
problems, as found in the case of Vioxx.
More... 12/17/04*
